Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has a revenue of INR 79,785.2 million, with a gross profit of INR 46,631.1 million and an operating income of INR 12,092.8 million. The company's net income is INR 8,458.1 million, and it has 580.8 million shares outstanding, both basic and diluted. The liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's profitability is reflected in its gross margin of 58.4% and an operating margin of 15.2%, which are in line with the industry's preferred metrics. The net profit margin is 10.6%, indicating a strong ability to convert revenue into profit. These metrics suggest that Aurobindo Pharma Ltd is performing well in terms of profitability and returns compared to the industry median. Aurobindo Pharma Ltd's revenue is primarily concentrated in the pharmaceuticals segment, with a significant portion derived from the Indian market. The company's geographic exposure is largely domestic, with limited international revenue reported in the available data. This concentration may pose a risk if the domestic market experiences regulatory or economic challenges. The company's growth trajectory is positive, with a strong revenue base and consistent profitability. Analysts have provided a mean price target of INR 1,397.50 and a median price target of INR 1,425.00, indicating a generally optimistic outlook. The mean recommendation score of 2.04 suggests a favorable sentiment among analysts, with 9 strong-buy and 12 buy ratings. The risk assessment for Aurobindo Pharma Ltd indicates a low dilution risk, with no significant dilution sources identified in the available documents. However, the liquidity risk remains unassessed due to the lack of balance-sheet data and no going-concern language in the source documents. This uncertainty could affect the company's ability to meet short-term obligations. Recent events and filings do not indicate any major disruptions or significant changes in the company's operations. The absence of recent transcripts or notable filings suggests a stable operational environment. However, the lack of detailed disclosures may limit the visibility into the company's strategic direction and potential risks.